For many years, litigation funding was explained through the simplest of legal stories: David versus Goliath. A smaller claimant, short of resources, used outside capital to pursue a larger and better-funded defendant. It was an access-to-justice story, and a powerful one.
But it is no longer the whole story.
A more sophisticated market is now emerging. Medium and large companies, including businesses perfectly capable of paying their own legal bills, are increasingly using litigation funding for a different reason. They are not asking whether they can afford to litigate. They are asking whether they should carry the cost, risk, and timing uncertainty of litigation on their own financial statements.
That is a very different question.
For a company, litigation is an awkward financial asset. The legal claim may have real value, sometimes very substantial value, but the accounting treatment rarely reflects that value in a helpful way. The costs arrive first. Legal fees are paid from cash flow and move through the income statement. The potential recovery sits somewhere in the future, uncertain in timing and outcome. Appeals, reviews, enforcement delays, and counterparty behaviour can stretch the process across several financial years.
This creates a mismatch that finance teams understand immediately. The cost is current. The asset is deferred. The downside is carried by the company. The upside is uncertain and often only recognised when cash is finally received.
There is also a hidden cost that is often underestimated: opportunity cost.
Capital used to fund litigation is capital not being used in the business. For a profitable company, that is not a theoretical point. The same capital could have supported working capital, inventory, expansion, acquisitions, debt reduction, new contracts, or shareholder returns. If the company can generate attractive returns from its own operations, then every rand, dollar, or pound committed to litigation has a second cost attached to it: the return the business did not earn.
That is why self-funding litigation is not always the cheapest option, even for a company with cash.
A company may believe it is saving money by avoiding a funder’s return. But if the litigation runs for four years, absorbs management attention, depresses earnings, consumes cash, and ultimately fails, the real loss is not only the legal spend. It is the legal spend, the adverse cost risk, and the commercial return that capital could have generated elsewhere.
Litigation funding changes that calculation.
Properly structured, it allows a company to move litigation from an open-ended cost exposure into a managed financial position. The funder may take over future legal costs. After-the-Event insurance may protect against adverse cost exposure. Historic legal spend may be partially monetised. The company may give up part of the upside if the case succeeds, but in return it protects liquidity, reduces downside risk, and improves financial predictability.
That trade-off is the point. Litigation funding is not free money. It is risk transfer.
Consider a mid-sized company with a strong commercial claim worth $50 million. It has already spent $2 million pursuing the claim. It expects to spend another $5 million over the next four years. If it loses, it may face $4 million in adverse costs. Assume the company can generate a 15% return on capital inside its own business.
If the company self-funds, the numbers look simple at first. It spends another $5 million and keeps all the upside if it wins. But that view is incomplete.
Over four years, that $5 million is no longer available to the operating business. It cannot be used for growth, stock, plant, acquisitions, debt reduction, or margin improvement. The legal spend also flows through the income statement, reducing profitability and creating volatility. The adverse cost exposure remains a downside risk. The $2 million already spent remains trapped in the case.
If the claim fails, the company may have lost $7 million in legal costs, may face further adverse cost exposure, and has also given up the return that the $5 million could have produced in the business during that period.
Now compare that with a funded structure.
The funder takes over the remaining legal budget. ATE insurance protects the adverse cost exposure. Part of the historic spend may be monetised, releasing cash back into the company. The company no longer funds the litigation from operating cash flow. The income statement is protected from future legal costs. The balance sheet is less exposed to contingent risk. Management retains participation in the upside, but with materially less downside.
The legal merits have not changed. The financial profile has.
That distinction is critical.
Modern litigation funding is not simply about helping a claimant afford litigation. It is about separating the legal asset from the operating business. The claim can continue, but it does not have to distort earnings, consume cash, or create uncertainty for shareholders.
This is particularly important where claims have already reached judgment.
A company may win a case and still not have cash. The losing party may appeal. A review may follow. Enforcement may take time. Payment may be delayed. The company may have a valuable judgment on paper, but from a finance perspective the asset remains illiquid.
Judgment monetisation and judgment bridging solve a different part of the same problem.
They allow a company to convert part of a judgment or expected recovery into cash today. Instead of waiting for appeal periods, enforcement processes, or payment cycles to conclude, the company can bring future value into the present financial period. That can support liquidity, reduce exposure to delay, and allow management to close the economic effect of litigation within a defined reporting cycle.
For financial directors, that matters. Litigation does not always need to remain an unresolved variable dragging across multiple financial years. In the right circumstances, it can be financed, insured, bridged, or monetised.
The implications also extend into corporate transactions.
In mergers and acquisitions, unresolved litigation can complicate valuation. Buyers may discount the business, request indemnities, delay closing, or treat the claim as an uncertain liability rather than a potential asset. A funded or monetised legal asset is easier to understand. The litigation can be ring-fenced. The operating business can be valued more cleanly. The upside can be preserved without allowing the dispute to contaminate the transaction.
This is where lawyers and finance teams need to speak the same language.
For lawyers, the question is often whether the claim has merit. For finance teams, that is only the beginning. They also need to understand duration, cost, cash flow impact, adverse cost exposure, enforcement risk, accounting treatment, and opportunity cost.
A strong claim can still be a poor financial position if it consumes too much capital for too long.
Conversely, a funded claim may become more attractive because the downside is controlled and the company’s capital remains available for its core business.
None of this guarantees success. Funders do not make weak claims strong. ATE insurance does not remove every risk. Monetisation comes at a cost. The company gives up part of the recovery in exchange for liquidity, certainty, and protection.
But that is how risk markets work.
Companies routinely insure, hedge, refinance, securitise, and transfer risk in other parts of their business. Litigation funding applies the same logic to legal assets.
That is why the David versus Goliath narrative is now too narrow. Litigation funding still plays that role, but the corporate market is moving beyond it. For medium and large companies, the question is increasingly one of capital efficiency.
Should the company spend its own cash on a four-year legal process, or should that capital be deployed into the business?
Should uncertain legal costs continue to affect earnings, or should they be transferred?
Should adverse cost exposure remain on the balance sheet, or should it be insured?
Should a judgment sit illiquid through an appeal, or should part of that value be brought forward?
These are not only legal questions. They are boardroom questions.
The companies that understand this first will treat litigation differently. They will not see claims merely as disputes to be won or lost. They will see them as financial assets with risk, duration, cost, and liquidity characteristics.
That requires a more disciplined internal process.
The starting point is visibility. Many companies do not have a consolidated view of their legal assets and exposures. Claims may sit across business units, external counsel, jurisdictions, and reporting lines. Costs are tracked, but value is not always assessed in a structured way. The first step is to identify what exists: live claims, potential claims, judgments, contingent recoveries, enforcement rights, and associated liabilities.
The second step is classification.
Not all legal assets are the same. Some are strategically important to the business. Others are purely financial. Some are early-stage and uncertain. Others are post-judgment, with defined recovery pathways but timing risk. Each category may require a different approach: self-funding, partial funding, full funding, ATE insurance, judgment monetisation, bridging, or sale.
The third step is risk pricing.
This is where many internal processes fall short. Legal teams are well placed to assess merits. Finance teams are well placed to assess cost. But the intersection between the two is where the real structuring question sits: duration risk, enforcement risk, counterparty credit, adverse costs, quantum sensitivity, opportunity cost, and timing of recovery.
Only after those questions are properly assessed can a company decide how the asset should be managed.
The objective is not to fund every claim. It is to decide which risks the company should retain, which it should transfer, and which assets it should monetise.
This is also where specialist advisory becomes relevant.
Accessing litigation funders, ATE insurers, and structured capital providers is not simply a matter of introduction. The legal asset needs to be packaged correctly. The commercial terms need to be aligned with the company’s financial objectives. The funding structure needs to protect downside without giving away unnecessary upside.
In practice, this sits between legal strategy and corporate finance.
That is the space in which Wild Dog operates: helping companies, law firms, and asset holders assess legal assets, structure funding and risk transfer, and access appropriate capital or insurance markets. Not every claim justifies that approach. But where the numbers are meaningful, the discipline can materially improve how litigation sits within the business.
For corporates, that is the real shift.
Litigation funding is no longer just a legal lifeline.
It is becoming a balance sheet tool.
At Wild Dog, we work at the intersection of litigation funding, ATE insurance, and structured capital, helping attorneys and their clients translate legal claims into investable outcomes. For those who want to subscribe and follow how legal claims can be structured into fundable, recoverable outcomes, I’ve put the newsletter link below
https://www.linkedin.com/newsletters/wild-dog-litigation-funding-7399383352073654272/